{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-082784","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.255870+00:00","generated_at":"2026-06-04T04:59:54.113998+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO","bullets":["Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.","Kenneth Galbraith, Chair, President, and CEO, appointed interim CFO, assuming principal financial and accounting duties.","Company has initiated a search for a new permanent CFO.","Mr. Galbraith's compensation arrangements remain unchanged per prior filings.","No family relationships or arrangements with other persons regarding the appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-082784","json":"https://secwatch.observer/filing/0001193125-24-082784.json","markdown":"https://secwatch.observer/filing/0001193125-24-082784.md","text":"https://secwatch.observer/filing/0001193125-24-082784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/d806103d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:59:54.113998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"190a3dde6d","claim":"Kenneth Galbraith was appointed as interim Chief Financial Officer at Zymeworks Inc..","evidence_excerpt":"the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"1929330702","claim":"Dr. Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..","evidence_excerpt":"On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312524082784/0001193125-24-082784-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"removed"},{"label":"Role","value":"Senior Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}